Please login to the form below

Not currently logged in
Email:
Password:

Eucomed to review technology conferences

Eucomed is to enforce a system to review and approve third-party, medical technology conferences in accordance with its Code of Practice

Eucomed, Europe's association for the medical technology industry, is to enforce a system to review and approve third-party medical educational conferences in accordance with its Code of Practice.

The process is the first of its kind in the healthcare industry, with appraisal criteria containing aspects related to scientific programmes, location and venues.

Currently, Eucomed's members are able to sponsor educational conferences such as medical congresses, seminars and training courses in order to promote scientific knowledge and medical advancement, provided that the conferences comply with the Eucomed Code of Ethical Business Practice as determined by the individual Eucomed member.

The new pre-vetting system aims to simplify decision-making by providing uniform compliance determinations applicable to all Eucomed members.

The independent Eucomed Compliance Panel will hold responsibility for vetting conferences. Its chairman is John McLoughlin, a lawyer specialising in medical devices.

Describing the vetting process, McLoughlin said: "Eucomed members are required to follow the assessments which are issued by the Panel's compliance officer or the Panel itself."

If a conference receives a negative assessment, Eucomed members will not be allowed to sponsor either the conference or individual healthcare professionals who wish to attend the conference.

The outcome of each assessment will be made public on a dedicated website and relevant stakeholders will be notified.

John Wilkinson, Eucomed's CEO, said the system was "key" to increase the consistency and transparency of the medical technology industry behaviour.

He said: "We, as an industry, have to make sure that all our relationships with healthcare professionals remain beyond reproach. This is why Eucomed fully supports this initiative."

The review process will begin as a pilot, and will be evaluated 6-12 months after its launch.

17th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics